Acadia Pharmaceuticals Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; quarterly figures below are for Q4 2022. Acadia is a biopharmaceutical company whose only marketed product during the period was NUPLAZID (pimavanserin), approved in the U.S. for Parkinson’s disease psychosis. Trofinetide for Rett syndrome was under FDA review.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue, all NUPLAZID net sales | $517.2 million | $484.1 million |
| Gross profit / margin | $507.1 million / 98.0% | $473.3 million / 97.8% |
| Research and development | $361.6 million | $239.4 million |
| Selling, general and administrative | $369.1 million | $396.0 million |
| Operating loss | $(223.6) million | $(170.4) million |
| Net loss / diluted loss per share | $(216.0) million / $(1.34) | $(167.9) million / $(1.05) |
| Operating cash flow | $(114.0) million | $(125.7) million |
| Cash, cash equivalents and investments at year-end | $416.8 million | $520.7 million |
Revenue grew 6.8%, mainly due to a higher average gross selling price. R&D rose substantially, including a $60 million upfront Stoke collaboration payment and a $10 million Neuren milestone, alongside higher pipeline development costs. SG&A fell as NUPLAZID commercial spending was optimized, partly offset by trofinetide launch preparation. Net loss widened 28.7% despite lower operating cash use. The company reported no debt in the balance sheet; liabilities included $62.0 million of operating lease obligations. Current assets were $507.9 million versus current liabilities of $125.6 million.
Q4 2022: Revenue was $136.5 million versus $130.8 million in Q4 2021. Net loss was $41.7 million versus $43.1 million, and loss per share was $0.26 versus $0.27.
Outlook, risks and notable items
- Management expected available cash and investments to fund planned operations for at least 12 months from the filing, while noting possible future financing needs and continued losses over the next few years.
- Trofinetide’s NDA had an FDA target action date of March 12, 2023. Approval and commercial success were uncertain; the pivotal trial showed meaningful gastrointestinal adverse events, including diarrhea in 80.6% and vomiting in 26.9% of treated participants.
- Top-line results from the Phase 3 ADVANCE-2 schizophrenia study were expected in early 2024. ACP-204 was in Phase 1, with further Alzheimer’s disease psychosis studies planned subject to progress.
- NUPLAZID sales remain central to the business. Four customers represented approximately 73% of FY2022 revenue. The product also has an ongoing FDA post-marketing commitment in predominantly frail and elderly patients.
- Generic-patent litigation involving NUPLAZID was ongoing; a joint trial was scheduled for May 2023. Hetero settled and could launch its generic product July 27, 2038, subject to earlier-launch triggers. A securities class action was also pending. Acadia reported no loss accrual beyond legal fees and said it could not estimate potential losses.
- Other material risks include regulatory and clinical-trial outcomes, outsourced manufacturing and supply concentration, reimbursement and drug-pricing changes, patent challenges, and lingering COVID-19 and geopolitical impacts.
Investor verification checklist
- Track NUPLAZID sales growth, pricing, payer rebates and customer concentration.
- Confirm trofinetide’s FDA decision, launch readiness, uptake and safety profile.
- Monitor cash burn, investment balances and spending on pipeline programs and collaborations.
- Follow the NUPLAZID generic patent cases and securities litigation for potential financial or commercial effects.
- Verify progress and timing for ADVANCE-2, ACP-204 and the remaining NUPLAZID post-marketing commitment.